T4K3.news

Study finds contraceptive jab increases brain tumour risk

New research shows women using Depo Provera for a year face higher rates of meningiomas.

July 23, 2025 at 04:00 PM

Contraception used by thousands increases risk of brain tumour, study finds

A recent study suggests that long-term users of a popular contraceptive may face elevated risks.

New study links contraceptive jab to increased brain tumour risk

A new study indicates that women using the contraceptive injection Depo Provera face a significantly increased risk of developing meningiomas, a common type of brain tumour. Women who use the drug for more than one year are reportedly 3.5 times more likely to develop this condition. This finding adds to existing concerns, as it is the third significant investigation revealing a similar connection in over a year. In the UK, around 10,000 prescriptions for Depo Provera are issued monthly, prompting hundreds of women to consider legal action against Pfizer, the drug's manufacturer, alleging they were not adequately warned about the risks. Legal actions, including a class action suit in the US, emphasize the growing controversy surrounding this contraceptive method.

Key Takeaways

✔️

Women on Depo Provera for over a year face 3.5 times higher brain tumour risk.

✔️

Meningiomas are a serious but often slow-growing type of brain tumour.

✔️

Legal actions against Pfizer highlight concerns over drug safety compliance.

✔️

Three studies have consistently linked the jab to elevated tumours risk.

✔️

The UK health authority calls for stronger warnings on contraceptive injectables.

✔️

Women may need to consider alternative contraceptive methods amidst rising concerns.

"Women concerned about this risk may want to consider opting for alternative contraceptives."

Researcher Dr Mahyar Etminan advises women to explore safer options following the findings.

"This new study reinforces the need for legal action against Pfizer, with the hope of bringing justice for the women who have never been warned."

Virginia Buchanan, representing women affected, stresses the importance of legal accountability.

The revelations regarding Depo Provera highlight a pivotal moment in women's health and pharmaceutical accountability. With studies documenting the drug’s association with serious health risks, women who have trusted this long-standing contraceptive may feel betrayed. The push for legal action against Pfizer signals a demand for transparency and greater caution in how contraceptive options are marketed and prescribed. The controversy is far-reaching—beyond individual health concerns, it raises fundamental questions about the regulatory frameworks overseeing drug safety, the dissemination of risks, and the responsibilities of pharmaceutical companies towards their consumers.